Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06068270
Recruiting Not applicable

Effect of MOPs During Orthodontic Movement in Periodontitis Patients

NCT06068270 · tracked via the Priya Life Science Spain tracker
Sponsor
Universidad Complutense de Madrid
Phase
Not applicable
Started
2023-12-15
Last updated
2025-03-27

Condition(s) studied

Stage IV PeriodontitisOrthodontic Tooth Movement

Investigational drug(s) / intervention(s)

Micro-ostoperforations (MOPs)

Micro-ostoperforations (MOPs): 3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)

Study summary

Micro-osteoperforations (MOPs) cause cortical bone injuries and consequently increase the expression of inflammatory mediators, allowing for increased bone and periodontal ligament remodeling associated with orthodontic movement. It remains unclear the effect of orthodontic intrusion combined with MOPs application on teeth with reduced periodontium. The general objective will be to determine the efficacy of MOPs during orthodontic tooth movement (OTM) in terms of periodontal and orthodontic outcomes in stage IV periodontitis patients, case type 2 with pathological tooth migration (PTM), characterized the presence of at least one flared tooth of the upper-anterior sextant with an intrabony defect (intrabony component \<5mm)

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: Patients will be included if agreeing to undertake combined periodontal and orthodontic therapy following the clinical practice guideline of stage IV periodontitis patients, and fulfilling the following criteria: * adult patients older than 18-year-old; * systemically healthy (see exclusion criteria); * diagnosed as stage IV (Papapanou et al., 2018) case-type 2 (Herrera et al. 2022) periodontitis; * the presence of at least one flared tooth of the upper-anterior sextant with an intrabony defect (intrabonny component \<5mm) (experimental teeth); * in need of orthodontic therapy. Exclusion Criteria: * systemic diseases (diabetes mellitus, obesity, cardiovascular diseases); * any medication that could affect the level of inflammation, (such as chronic antibiotics, phenytoin, cyclosporin, anti-inflammatory drugs, systemic corticosteroids, or calcium channel blockers); * pregnant or lactating woman; * inability to respond questions or to attend follow-up visits; * extreme skeletal malocclusions requiring orthognathic surgery; * patients smoking more than 10 cigarettes/day; and * the presence of PD greater or equal to 5mm with BOP after step 3 of periodontal therapy

Primary outcome measure(s)

  • CAL — 12 months
    clinical attachment level (CAL) in mm

Trial sites (1)

FacilityCityRegionStatus
Faculty of Odontology, University Complutense Madrid Madrid Madrid Recruiting

More Universidad Complutense de Madrid trials in Spain

Clinical Evaluation of Resin Matrix Ceramic Posterior Crowns Recruiting
Dry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points? Starting soon
Acute Effects of Active Breaks and Physically Active Learning in University Students Starting soon
Optimization of Surgical Hand Preparation Using Sorbectol Recruiting
Effect on Periodontal Phenotype of Flapless Piezoincission During Orthodontic Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06068270 on ClinicalTrials.gov ↗ ← All trials in Spain